Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms
Abstract
Although the single-nucleotide polymorphism (SNP) rs12979860 in the IL28B gene is a better predictor of sustained virological response to treatment of chronic hepatitis C (CHC) than other baseline factors, some CHC patients with the favorable C allele cannot achieve a sustained virological response when treated with peginterferon plus ribavirin. The aim of this study was to examine baseline factors as predictors of rapid virological response (RVR) and complete early virological response (cEVR) to peginterferon alfa-2a plus ribavirin treatment in Chinese CHC patients with hepatitis C virus (HCV) g...
Source: Archives of Virology - February 18, 2015 Category: Virology Source Type: research
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
Conclusion
The addition of vaniprevir to PR was associated with an increase in RVR and SVR. Combined with a generally safe and well-tolerated profile, these data supported the further evaluation of vaniprevir in Japanese patients with HCV GT1 infection (#NCT00880763). (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 1, 2015 Category: Gastroenterology Source Type: research
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial
Conclusions
In treatment-naive haemodialysis patients with HCV-2 infection, combination therapy with peginterferon plus low-dose ribavirin achieved a greater SVR rate than peginterferon monotherapy. Most haemodialysis patients can tolerate combination therapy.
Trial registration number
ClinicalTrial.gov number, NCT00491244. (Source: Gut)
Source: Gut - January 8, 2015 Category: Gastroenterology Authors: Liu, C.-H., Liu, C.-J., Huang, C.-F., Lin, J.-W., Dai, C.-Y., Liang, C.-C., Huang, J.-F., Hung, P.-H., Tsai, H.-B., Tsai, M.-K., Lee, C.-Y., Chen, S.-I., Yang, S.-S., Su, T.-H., Yang, H.-C., Chen, P.-J., Chen, D.-S., Chuang, W.-L., Yu, M.-L., Kao, J.-H. Tags: Hepatology Source Type: research
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
Publication date: January 2015 Source:The Lancet Haematology, Volume 2, Issue 1 Author(s): Franck E Nicolini , Gabriel Etienne , Viviane Dubruille , Lydia Roy , Françoise Huguet , Laurence Legros , Stéphane Giraudier , Valérie Coiteux , Agnès Guerci-Bresler , Pascal Lenain , Pascale Cony-Makhoul , Martine Gardembas , Eric Hermet , Philippe Rousselot , Shanti Amé , Marie-Claude Gagnieu , Christine Pivot , Sandrine Hayette , Veronique Maguer-Satta , Madeleine Etienne , Stéphanie Dulucq , Delphine Rea , François-Xavier Mahon Background Nilotinib is now recommended for patients with newly diag...
Source: The Lancet Haematology - January 8, 2015 Category: Hematology Source Type: research
Study of pruritus in chronic hepatitis C patients.
CONCLUSION: Patients with chronic hepatitis C experience pruritus more than those without. Serum TARC levels do not correlate with pruritus severity in chronic hepatitis C patients.
PMID: 25548485 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - December 21, 2014 Category: Gastroenterology Authors: Suzuki K, Tamano M, Katayama Y, Kuniyoshi T, Kagawa K, Takada H, Suzuki K Tags: World J Gastroenterol Source Type: research
Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report
Conclusions
The co-administration of boceprevir and warfarin resulted in a subtherapeutic international normalized ratio. Upon starting boceprevir, his warfarin dose was increased by 75% over 2 months to achieve a therapeutic international normalized ratio. After discontinuing boceprevir, his maintenance dose of warfarin was 37% greater than his original dose. This is an original case report which demonstrates the significant effects of this drug interaction and the importance of monitoring international normalized ratio. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - December 17, 2014 Category: Journals (General) Source Type: research
Drug-induced anaemia: a decade review of reporting to the Italian Pharmacovigilance data-base
Conclusions A possible signal was detected for peginterferon alfa-2a, ribavirin and flu vaccine in the occurrence of autoimmune haemolytic anaemia. A great involvement of clopidogrel, enoxaparin, warfarin, ticlopidine and acetylsalicylic acid in preventable DDI-induced anaemia was detected, highlighting a poor awareness among healthcare providers on this issue. (Source: International Journal of Clinical Pharmacy)
Source: International Journal of Clinical Pharmacy - December 17, 2014 Category: Drugs & Pharmacology Source Type: research
[Articles] Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial
Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated in HCV genotype 1-infected previous non-responders and was non-inferior to telaprevir, thus providing an alternative treatment in areas of the world where all-oral HCV regimens are not available or accessible. (Source: The Lancet Infectious Diseases)
Source: The Lancet Infectious Diseases - December 5, 2014 Category: Infectious Diseases Authors: K Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, Ola Weiland, Andrzej Horban, Carol Stanciu, Federico Guillermo Villamil, Pietro Andreone, Jacob George, Elisabeth Dammers, Min Fu, Darryl Kurland, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Thierry Verbinnen, Ja Tags: Articles Source Type: research
SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
Authors: D'heygere F, George C, Habersetzer F, Tripathi D, Q Pan C, Giron JA, Schmitz M, Tatsch F
PMID: 24558225 [PubMed - indexed for MEDLINE] (Source: Annals of Hepatology)
Source: Annals of Hepatology - December 2, 2014 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection
Conclusion
In summary, the serum miR-122 level is highly correlated with the HBsAg level in HBV/HCV dually infected patients and may serve as a biomarker to predict posttreatment HBsAg decline. (Source: Hepatology International)
Source: Hepatology International - November 18, 2014 Category: Infectious Diseases Source Type: research
Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study
Conclusions Peginterferon alfa-2a treated patients were also more likely to be HCV RNA negative at the end of treatment (67.3% vs. 57.7%), but this difference did not reach statistical significance. Multivariate logistic regression analysis found that SVR was associated with low fibrosis stage (F1–2 by Scheuer; p =0.001) and low serum HCV RNA level (<400,000IU/L; p =0.023). While both forms of peginterferon showed similar efficacy as measured by SVR, use of peginterferon alfa-2b could lower the number of patients receiving unnecessary treatment beyond 12 weeks. (Source: Advances in Medical Sciences)
Source: Advances in Medical Sciences - October 23, 2014 Category: Biomedical Science Source Type: research
Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
Conclusion Our study shows that the SVR rates are similar in hemophilic and nonhemophilic patients with chronic HCV infection who receive PEG-IFN-α-2a plus RBV in Taiwan. The rate of AEs also resembled other studies in nonhemophilic patients in Taiwan. No patient suffered from severe bleeding. However, large-scale, well-conducted studies are still needed to verify the treatment efficacy and safety. (Source: Journal of the Formosan Medical Association)
Source: Journal of the Formosan Medical Association - October 12, 2014 Category: Journals (General) Source Type: research
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial
Conclusions
It is unclear whether the extension of peginterferon alfa-2a/ribavirin treatment may benefit HCV genotype 2/3 patients who do not achieve RVR. The study was stopped early because recruitment was slower than anticipated, and this may have limited the statistical impact of these findings. (Source: Hepatology International)
Source: Hepatology International - October 1, 2014 Category: Infectious Diseases Source Type: research
A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon‐α variant with Pegasys in healthy subjects
ConclusionsThe tolerance, pharmacokinetic and pharmacodynamic characteristics of PEG‐IFN‐SA supported its administration by subcutaneous injection, at a single dose of 1.5 μg/kg or 2.0 μg/kg per week. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - October 1, 2014 Category: Drugs & Pharmacology Authors: Li Zheng, Ping Mao Li, Ping Zhong Gou, Wang Ying, Xu Nan, Ming Yong Cai, Hua Luo Tags: PK‐PD relationships Source Type: research
Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.
CONCLUSION: Elderly HCV patients differ in clinical characteristics and treatment outcome from younger patients and demand special attention from their practitioner.
PMID: 25152602 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - August 21, 2014 Category: Gastroenterology Authors: Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, Stoll S, Alshuth U, Lohse AW, Lueth S Tags: World J Gastroenterol Source Type: research
